A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.

Authors
Valsamo AnagnostouSara MooreJanet Dancey
Journal
Journal of Clinical Oncology
Published
June 1, 2024
Sign in to comment
Add a comment...

No comments yet. Start the conversation!

Your contribution could help open science.

Supporters

Support the authors with ResearchCoin

Topics

DOI

10.1200/jco.2024.42.16_suppl.tps8669

License

Unknown License
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer. - Comments